Dr Moira Cruickshank
Research Fellow
- 51cg
-
- Email Address
- m.cruickshank@abdn.ac.uk
- Office Address
Health Services Research Unit
3rd Floor Health Sciences Building
Foresterhill
Aberdeen
AB25 2ZD- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
Moira Cruickshank is a Research Fellow in the Evidence Synthesis programme of ACE.
Moira was a Police Officer in the Metropolitan Police Service before returning to full time education at the 51cg in 2002, graduating with BSc (Hons) Psychology in 2006, MRes Psychology in 2007 and PhD Psychology in 2011. Since then, Moira has been a systematic reviewer within the Evidence Synthesis programme and is involved in technology assessment appraisals and health technology assessment reviews.
- Publications
-
Page 2 of 6 Results 11 to 20 of 56
The effects and safety of testosterone replacement therapy for men with hypogonadism: The TestES evidence synthesis and economic evaluation
Health Technology Assessment, vol. 28, no. 43Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
- [ONLINE]
Fruquintinib for previously treated metastatic colorectal cancer [ID6274]: NICE Single Technology Appraisal
Commissioned by National Institute for Health and Care Excellence (NICE). Aberdeen HTA GroupBooks and Reports: Commissioned Reports- [ONLINE]
What is the impact of long-term COVID-19 on workers in healthcare settings? A rapid systematic review of current evidence
PloS ONE, vol. 19, no. 3 , e0299743Contributions to Journals: Review articles- [ONLINE] DOI:
- [OPEN ACCESS]
- [ONLINE]
Cost-effectiveness of testosterone treatment utilising individual patient data from randomised controlled trials in men with low testosterone levels
Andrology, vol. 12, no. 3, pp. 477-486Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
- [ONLINE]
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments
National Institute for Health and Care Excellence (NICE). 20 pagesBooks and Reports: Commissioned Reports- [ONLINE]
- [ONLINE]
- [ONLINE]
Netarsudil-latanoprost for previously treated openangle glaucoma or ocular hypertension [ID1363]: NICE Single Technology Appraisal
Commissioned by National Institute for Health and Care Excellence (NICE). Aberdeen HTA GroupBooks and Reports: Commissioned Reports- [ONLINE]
- [ONLINE]
Clinical Predictors Of Symptomatic Benefit In Men With Low Testosterone During Testosterone Treatment Compared With Placebo:: Results Of Individual Patient And Aggregate Data Meta-analyses
Annual Meeting of the Endocrine Society 2023, bvad114.1704Contributions to Journals: Abstracts- [ONLINE] DOI:
Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis
The Lancet Healthy Longevity, vol. 4, no. 10, pp. e561-e572Contributions to Journals: Articles- [ONLINE]
- [ONLINE] DOI:
- [OPEN ACCESS]
Deucravacitinib for treating moderate-to-severe plaque psoriasis
Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence. 155 pagesBooks and Reports: Commissioned Reports- [ONLINE]
- [ONLINE]
Secukinumab for Moderate-to-Severe Hidradenitis Suppurativa [ID4039]: NICE Single Technology Appraisal
Commissioned by National Institute for Health and Care Excellence (NICE). Aberdeen HTA GroupBooks and Reports: Commissioned Reports- [ONLINE]
- [ONLINE]